Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Rwanda has been steadily increasing over the past few years.
Customer preferences: Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are the primary consumers of immunosuppressants in Rwanda. These patients require long-term medication to manage their symptoms and prevent the progression of their diseases. Additionally, organ transplant patients also require immunosuppressants to prevent their bodies from rejecting the transplanted organs.
Trends in the market: The immunosuppressants market in Rwanda has been growing due to an increase in the prevalence of autoimmune diseases and organ transplantation. The rise in public awareness about these diseases and their treatment options has also contributed to the growth of the market. However, the market is still relatively small due to limited access to healthcare and a lack of affordability for many patients.
Local special circumstances: Rwanda has made significant progress in improving its healthcare system over the past few years. The government has implemented various policies and initiatives to increase access to healthcare, including expanding health insurance coverage and investing in the construction of new healthcare facilities. However, despite these efforts, many Rwandans still face challenges in accessing healthcare due to poverty and geographic barriers.
Underlying macroeconomic factors: Rwanda's economy has been growing steadily over the past few years, with a focus on developing its healthcare sector. The government has prioritized healthcare as a key sector for economic growth and has invested heavily in its development. However, the country still faces challenges in terms of poverty and income inequality, which limit access to healthcare for many Rwandans. Additionally, the COVID-19 pandemic has had a significant impact on the country's economy and healthcare system, potentially affecting the growth of the immunosuppressants market in the short term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
